Krystal Biotech Inc (KRYS)

Pretax margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	95,356	57,403	108,381	59,126	12,897	-29,812	-140,409	-135,307	-139,975	-129,729	-115,468	-103,723	-69,570	-58,147	-52,168	-42,638	-32,167	-27,141	-21,803	-20,318
Revenue (ttm)	US$ in thousands	293,354	247,796	172,511	103,808	58,154	10,946	2,390	809	0	0	0	0	0	0	0	0	0	0	0	542
Pretax margin		32.51%	23.17%	62.83%	56.96%	22.18%	-272.36%	-5,874.85%	-16,725.22%	—	—	—	—	—	—	—	—	—	—	—	-3,748.71%

December 31, 2024 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $95,356K ÷ $293,354K
= 32.51%

The pretax margin of Krystal Biotech Inc indicates the company's profitability before taxes as a percentage of its total revenue.

As of March 31, 2020, the pretax margin was -3,748.71%, which suggests that the company was incurring significant losses relative to its revenue. The negative margin indicates that the company's operating expenses and/or financing costs were disproportionately high compared to its revenue during that period.

Over the following quarters, the pretax margin data was not available, suggesting that either the company did not report this information or it was not applicable due to various reasons such as losses surpassing revenue or changes in accounting practices.

By March 31, 2023, the pretax margin had improved significantly to -16,725.22%, still negative but a notable enhancement from the previous year. This improvement might indicate better cost management or revenue generation strategies being implemented by the company.

In the subsequent quarters, there was a further improvement in profitability with the pretax margin transitioning into positive territory. Notably, by December 31, 2024, the pretax margin reached 32.51%, showcasing a substantial turnaround in the company's profitability. This uptrend suggests that Krystal Biotech Inc was able to control costs, boost revenue, or both, leading to a healthier pretax margin and improved financial performance.